Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) EPS (Weighted Average and Diluted): 2022-2024

Historic EPS (Weighted Average and Diluted) for Entrada Therapeutics (TRDA) over the last 3 years, with Dec 2024 value amounting to $1.68.

  • Entrada Therapeutics' EPS (Weighted Average and Diluted) fell 202.86% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.56, marking a year-over-year decrease of 260.00%. This contributed to the annual value of $1.68 for FY2024, which is 940.00% up from last year.
  • According to the latest figures from FY2024, Entrada Therapeutics' EPS (Weighted Average and Diluted) is $1.68, which was up 940.00% from -$0.20 recorded in FY2023.
  • Entrada Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at $1.68 for FY2024, and its period low was -$3.02 during FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.20 (2023), whereas its average is -$0.51.
  • Data for Entrada Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY skyrocketed of 940.00% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Entrada Therapeutics' EPS (Weighted Average and Diluted) stood at -$3.02 in 2022, then surged by 93.38% to -$0.20 in 2023, then spiked by 940.00% to $1.68 in 2024.